Introduction

Pfizer

Company name: Pfizer Limited

Address: Ramsgate Road

Sandwich

Kent CT13 9NJ

Telephone: 0845 300 8034 (Out of hours: 01304 616161)

Fax: 01737 332521

Email: UKVetLine@pfizer.com

Website: www.only4vets.co.uk

Presentation

A solution for injection, each 1ml dose containing live attenuated canine parvovirus, NL-35-D strain, low passage ≥ 107.0 CCID50, inactivated Leptospira canicola ≥ PD40 and inactivated Leptospira icterohaemorrhagiae ≥ PD40.

Uses

For the active immunisation of healthy puppies and dogs to prevent clinical signs and reduce infection or excretion due to canine parvovirus and to reduce clinical signs and infection due to Leptospira canicola and Leptospira icterohaemorrhagiae.

Onset of immunity occurs by approximately 2 weeks after the last dose of the Basic Vaccination Scheme.

The duration of immunity is at least 12 months.

Dosage and administration

Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously. Do not use chemically sterilised syringes or needles, as these will interfere with the effectiveness of the vaccine.

Basic Vaccination Scheme:

Puppies younger than 10 weeks of age:

Two doses of Vanguard CPV-L at least 14 days apart. The first dose can be given as young as 7 weeks of age. The second dose should not be given until at least 10 weeks of age.

Puppies 10 weeks of age and older:

A single dose of Vanguard CPV-L, followed by a single dose of Vanguard Lepto ci at least 14 days later.

Booster Vaccination:

Leptospiral components – annual booster vaccination is recommended.

Viral components – annual booster vaccination is recommended. However, should Veterinary Surgeons conduct a risk-benefit analysis for individual animals to determine the frequency of revaccination with Vanguard CPV-L, they should be aware of the following information. Serological data has indicated that most dogs, when given at least the first annual booster, can maintain protective levels of immunity to the viral components of Vanguard CPV-L for up to 4 years. For further information please contact the company.

Contra-indications, warnings, etc

Do not vaccinate unhealthy or pregnant animals.

Vaccinated dogs may have a transient swelling 4-6 hours after vaccination which resolves after approximately 7 days. If a systemic anaphylactic reaction occurs (e.g. vomiting) administer adrenaline or an equivalent.

Occasional, transient swellings may occur at the injection site after vaccination with an overdose. No treatment is necessary in most cases of overdose. However, if a systemic anaphylactic reaction occurs (eg vomiting) administer adrenaline or an equivalent.

The canine parvovirus vaccinal strain may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of this strain, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.

High levels of maternally derived antibodies (MDA) may interfere with the response to vaccination. Although the vaccine has been shown to be efficacious in the presence of levels of MDA that are likely to be encountered under field conditions, where for any reason it is likely that particularly high levels of MDA are present (for example against the CPV component), this should be taken into account when planning the timing of vaccinations.

Operator warning:

In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.

Pharmaceutical precautions

Store and transport at 2°C - 8°C. Do not freeze.

No information is available on the safety and efficacy from the concurrent use of this vaccine with any other except vaccines from the Vanguard™ range containing distemper virus, canine adenovirus or canine parainfluenzavirus. It is therefore recommended that no vaccines other than these should be administered within 14 days before or after vaccination with this product.

Do not mix with any other vaccine or immunological product.

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.

For animal treatment only.

Keep out of reach of children.

Legal category

POM-V

Packaging Quantities

Packs contain 25 doses of Vanguard CPV-L. Packs of disposable syringes with needles are also available.

Further information

Canine parvovirus disease in kennels and pet shops is a problem of intensive husbandry and must be treated as such. Without careful professional attention to management practices in such places, successful disease control may be difficult to achieve.

When used in accordance with the recommended vaccination regime, Vanguard CPV-L can aid in the reduction of environmental contamination with canine parvovirus.